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Abstract: Degarelix is a gonadotropin-releasing hormone (GnRH) antagonist for the treatment 
of patients with prostate cancer in whom hormonal therapy is indicated. Two phase II trials and 
one phase III have been published as full papers in the literature. In the dose-ﬁ  nding phase II 
studies an initial dose of 240 mg degarelix sc followed by a monthly injection of 80 mg or 
160 mg degarelix sc was sufﬁ  cient to keep testosterone levels   0.5 ng/ml. In a phase III trial 
it was demonstrated that degarelix was not inferior (in terms of testosterone suppression and 
prostate-speciﬁ  c antigen [PSA] decline) compared to standard hormonal therapy, ie, a GnRH 
agonist such as leuprolide. In fact, degarelix was associated with a faster testosterone suppression 
and PSA decline than leuprolide. Adverse events such as injection site reactions (40% vs  1%) 
and chills (4% vs 0%) were more commonly associated with degarelix. Also, degarelix is 
currently only available as one-month depot whereas in daily practice three-month depots (of 
GnRH agonists) are the preferred regimen. However, degarelix was recently approved by the 
US Food and Drug Administration for the treatment of advanced prostate cancer.
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Introduction
Prostate cancer is the most common malignancy in the US and in western Europe with 
an estimated 186,320 newly diagnosed cases in 2008 in the US and 28,660 men who 
died of prostate cancer in the US (incidence-mortality ratio of 6.5).1
The therapeutic options available predominantly depend on cancer stage as well 
as patient age and co-morbidity. In organ-conﬁ  ned prostate cancer the treatment is 
radical prostatectomy, external beam radiotherapy, or brachytherapy. In this stage of 
the disease, therapy is with curative intention and patients have an excellent prognosis.2 
Active surveillance or watchful waiting are also options in patients with low risk 
organ-conﬁ  ned prostate cancer (ie, clinical stage T1c-2a and Gleason score 6 and 
prostate-speciﬁ  c antigen (PSA) less than 10 and less than 33% of prostate biopsies 
positive for cancer).3 Primary androgen deprivation therapy might also be an option 
but without curative intention.4 However, androgen deprivation therapy is not regarded 
as standard in patients with localized prostate cancer.5
In metastatic prostate cancer and/or in patients who are not able to undergo the 
above treatment options because of their age and/or co-morbidity, the standard of 
care is androgen deprivation therapy.6 Watchful waiting may also be applied under 
the latter circumstances.
Huggins ﬁ  rst described the effect of castration on prostate cancer in 1941.7 This 
was the basis for the ﬁ  nding that prostate cancer cells need androgens for their growth. 
Without the receptor-mediated stimulus of androgens prostate cancer cells undergo 
apoptosis.8,9 Androgens are synthesized in the testes (95%) and in the adrenal glands 
(5%). The androgen synthesis underlies a hormonal regulation by the hypothalamic–
pituitary–gonadal axis in a negative feedback manner.Clinical Interventions in Aging 2009:4 216
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Based on these ﬁ  ndings, lowering testosterone levels 
either medically or surgically and/or blockade of the andro-
gen receptor represents the principal mechanism of androgen 
deprivation therapy of prostate cancer.10 Surgical castration 
can be done by bilateral orchiectomy. This is an effective 
procedure and not associated with relevant complications. 
The disadvantages are the possible negative psychological 
effects and the fact that no intermittent androgen deprivation 
therapy can be applied.11
Similar effects can be achieved by suppression of the 
gonadotropins luteinizing hormone (LH) and follicle-
stimulating hormone (FSH) with gonadotropin-releasing 
hormone (GnRH) agonists (eg, buserelin, goserelin, leupro-
lide, triptorelin) that desensitize the pituitary gland. This leads 
to a suppression of the LH synthesis and secretion followed 
by decreased stimulus for testosterone synthesis within the 
testicles. Another medical manipulation of this hormonal 
regulation can be achieved by blocking the androgen receptor 
with steroidal antiandrogens (eg, cyproterone acetate) or 
nonsteroidal antiandrogens (eg, bicalutamide, ﬂ  utamide).10 
However, the effect from androgen receptor blockade is 
considered to be less effective compared to LH-releasing 
hormone (LHRH) agonists (at least in metastatic disease).
Blocking the GnRH receptor with an antagonist in the 
pituitary gland is obviously the most logical way to achieve 
a fast and reversible decrease of LH, FSH, and testosterone 
without any clinical ﬂ  are. For a long time, however, GnRH 
antagonists showed relevant release of histamine from 
mast cells with acute systemic allergic reactions.12 Another 
constriction for clinical usefulness was limited solubility.13
Degarelix (Ferring Pharmaceuticals, Kiel, Germany) is 
the second GnRH antagonist that has been tested in a phase III 
trial.14 Degarelix has also proven its potential in achieving 
testosterone suppression without any evidence of clinical 
ﬂ  are. Additionally, no acute systemic allergic reactions were 
observed in patients treated with degarelix.15–17
This review aims to summarize phase II and III trials on 
degarelix for the treatment of patients with prostate cancer.
Efﬁ  cacy
Phase II dose-ﬁ  nding studies
There are four phase II dose-ﬁ  nding studies in the literature. 
Two of them are only available in abstract form and the 
remaining are full publications.
Data from a randomized phase II trial were presented 
by Weston and colleauges at the SIU congress in 2004.18 In 
this trial, 129 patients (age 55–87 years) with prostate cancer 
of all stages who were candidates for androgen deprivation 
therapy were treated in three different dose regimens between 
20 mg and 80 mg (arm A: degarelix 80/80/40 (ie, 80 mg 
on day 0, 80 mg on day 3, and 40 mg on day 28); arm B: 
degarelix 80/–/20; arm C: degarelix 40/40/40) administered 
on day 0, 3, and 28, respectively, and every 28 days thereafter. 
At baseline the median PSA level was 61 ng/ml. In this study, 
arm A was the most effective in achieving castration levels. 
At six-month follow-up 87.5%, 72.2%, and 58.8% of patients 
in arms A, B, and C had a testosterone  0.5 ng/ml.18
Results from a phase II multicenter, randomized dose-
escalating study testing degarelix in patients with prostate 
cancer were presented by Tammela and colleagues at the EAU 
congress in 2005.19 In this trial, 172 patients (age 48–89 years) 
with prostate cancer were included. These patients had a 
baseline median testosterone of 4.16 ng/ml and a median 
PSA of 38 ng/ml. Patients with metastatic prostate cancer 
(31%), locally advanced prostate cancer (36%), and local-
ized prostate cancer (26%) were included. Degarelix was 
administered sc at doses between 120 mg and 320 mg. The 
concentrations varied between 20 mg/ml and 60 mg/ml. 
The efﬁ  cacy could be evaluated in 169 patients at day 3 and 
day 28 by measurement of testosterone and PSA. Degarelix 
showed a dose- and concentration-dependent effect. A dose 
of 240 mg (40 mg/ml) resulted in castration (deﬁ  ned as 
testosterone  0.5 ng/ml) in 96% of the patients and was the 
most effective regimen.19
Two phase II studies have been conducted to evaluate the 
efﬁ  cacy of degarelix in different doses regimen in long-term 
follow-up.20,21
One open label, randomized phase II study with 
a starting dose of 200 mg degarelix sc and a monthly 
administration of 60 mg degarelix sc (200/60, arm A) or 
80 mg degarelix sc (200/80, arm B) was conducted in 
North America.20 In total, 127/176 screened patients with 
prostate cancer were enrolled. Patients had a median age 
of 76 years (range 47–93 years). Inclusion criteria were 
testosterone  2.2 ng/ml, PSA  2 ng/ml, and Eastern Coop-
erative Oncology Group (ECOG) score of 2 or less.
The primary endpoint was the proportion of patients with 
serum testosterone  0.5 ng/ml at all monthly measurements 
throughout the entire study period (ie, 12 months) and the 
proportion of patients with testosterone  0.5 ng/ml at all 
monthly measurements throughout the entire study period 
for those patients who had a testosterone  0.5 ng/ml after 
one month. Secondary endpoints included:
•  The proportion of patients with a testosterone  0.5 ng/ml 
at day 3
•  Time to 50% and 90% reduction in PSAClinical Interventions in Aging 2009:4 217
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•  Time to PSA progression (deﬁ  ned as PSA increase of 
50% or more from nadir and at least 5 ng/ml on two 
consecutive visits at least two weeks apart)
•  Pharmacodynamic parameters such as testosterone, PSA, 
dihydrotestosterone (DHT), LH, and FSH over time.
There were 23 patients with protocol violations, 16 with-
drawals due to inadequate testosterone suppression, six 
withdrawals due to adverse events, and 18 withdrawals due 
to other reasons. Therefore, 87/127 patients (69%) completed 
the study. Arm A comprised of 42 patients and arm B of 
45 patients without differences with regard to demographics 
and baseline characteristics. Median PSA at baseline was 
13.4 ng/ml (25th–75th percentile: 6.8–25.7 ng/ml). Median 
testosterone level at baseline was 4.13 ng/ml (25th–75th 
percentile: 3.06–5.11 ng/ml). Tumor stages were localized 
in 43%, locally advanced in 11%, metastatic in 19%, and not 
classiﬁ  able in 28% of patients. The Gleason score was 2–4 in 
5%, 5–6 in 32%, and 7–10 in 63% of cases, respectively.
In this study no testosterone surge was observed. At 
day 3, 89% of all patients had a testosterone  0.5 ng/ml 
without a statistically signiﬁ  cant difference between both 
groups (Table 1). After one month 88% of all patients had a 
testosterone  0.5 ng/ml (93% of patients in arm A compared 
to 83% of patients in arm B p = 0.073). The authors concluded 
that the starting dose was too low to achieve the predeﬁ  ned 
efﬁ  cacy success criterion of 95% of patients with a testosterone 
level  0.5 ng/ml. This was the rationale to test 240 mg as a 
starting dose in subsequent trials. Only 86% of patients in 
arm A and 77% of patients in arm B remained with their tes-
tosterone  0.5 ng/ml during the entire study period (p = not 
signiﬁ  cant, exact p value not given in publication). However, 
the majority of patients who had a testosterone  0.5 ng/ml 
after one month remained within this range for the entire study 
period (93% of patients in arm A compared to 98% of patients 
in arm B; p = 0.669). A PSA decline of 50% and 90% was 
achieved after 14 and 56 days in both treatment groups and a 
median reduction of 96% was documented after 12 months.20
The second study was conducted in Europe and South 
Africa and screened 216 patients with prostate cancer 
of whom 189 were randomized and 187 received study 
medication.21 Median age was 72 years (range 52–93 years). 
The inclusion criteria were similar to that in the North 
American study.20 Patients were randomized to six different 
dose regimens with an initial dosage of 200 mg degarelix 
or 240 mg degarelix followed by monthly maintenance 
dosage of degarelix 80 mg, degarelix 120 mg, or degarelix 
160 mg (groups 200/80, 200/120, 200/160, 240/80, 240/120, 
240/160), respectively. In all groups, a concentration of 
40 mg/ml degarelix was used. Thus, the sc injected volume 
varied between 2 ml and 4 ml.
Table 1 Published phase II and III trials on degarelix and prostate cancer: Efﬁ  cacy
Author Patients Study design Results
Gittelman20 N = 127 Phase II
Efﬁ  cacy and safety of degarelix with 
a starting dose of 200 mg followed 
by monthly maintenance doses of 60 mg 
or 80 mg for one year.
Testosterone suppression:
88% after one month, 93% and 98% 
(60 mg and 80 mg) after one year.
PSA response:
Median reduction 96% after one year
van Poppel21 N = 187 Phase II
Efﬁ  cacy and safety of degarelix with a 
200 mg or 240 mg starting dose followed 
by monthly maintenance doses of 80 mg, 
120 mg, or 160 mg for one year.
Testosterone suppression:
86% (200 mg) vs 95% (240 mg) after one 
month, 92% (80 mg), 96% (120 mg), 100% 
(160 mg) after one year.
PSA response:
Median reduction 97%–98% after one year
Klotz14 N = 610 Phase III
Efﬁ  cacy and safety of degarelix with 
a starting dose of 240 mg followed 
by monthly maintenance dose of 80 mg 
or 160 mg vs leuprolide 7.5 mg monthly.
Testosterone suppression:
97.2%, 98.3% in patients treated with 
degarelix (240/80 mg, 240/160 mg) and 
96.4% in patients treated with leuprolide 
after one year.
PSA response:
PSA decline from baseline was signiﬁ  cant 
faster in the degarelix groups than 
with leuprolide, PSA values not given in 
publication.
Abbreviation: PSA, prostate-speciﬁ  c antigen.Clinical Interventions in Aging 2009:4 218
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Primary endpoint was to determine the proportion of 
patients with testosterone  0.5 ng/ml after one month 
and every month thereafter. Results were given for the 
intention-to-treat (ITT) population (n = 187 patients). 
Secondary endpoints were the proportion of patients with 
testosterone  0.5 ng/ml up to one year for those patients with 
testosterone  0.5 ng/ml after one month, the proportion of 
patients with testosterone level  0.5 ng/ml at day 3, times 
to reach 50% and 90% reduction in PSA, time to reach PSA 
progression (deﬁ  ned as a PSA increase  50% and at least 
5 ng/ml compared to nadir on two consecutive visits at least 
two weeks apart), and pharmacodynamic parameters (serum 
testosterone, DHT, PSA, LH, and FSH over time).
There were four patients with protocol violations, 
16 withdrawals due to inadequate testosterone suppression, 
13 withdrawals due to adverse events, and 13 withdrawals 
due to other reasons. Therefore, 147/187 patients (78%) 
completed the trial. The median testosterone level at baseline 
was 4.13 ng/ml (25th–75th percentile: 3.37–5.19 ng/ml) and 
median PSA at baseline was 27.6 ng/ml (25th–75th percentile: 
12–55 ng/ml). Tumor stages were localized in 22%, locally 
advanced in 32%, metastatic in 19%, and not classiﬁ  able in 
22% of patients. The Gleason score was 2–4 in 19%, 5–6 in 
41%, and 7–10 in 39% of cases, respectively. There were 
no differences between the six groups except for median 
PSA which was 15.2 ng/ml in the 200/80 treatment group 
compared to 35.3 ng/ml in the 240/120 treatment group.
No testosterone surge was observed. At day 3, 88% of 
patients with degarelix 200 mg as initial dose and 92% of 
patients with degarelix 240 mg as initial dose had testosterone 
levels   0.5 ng/ml (Table 1). After one month a signiﬁ  cant 
higher proportion of patients who received degarelix 240 mg vs 
degarelix 200 mg as initial dose had a testosterone  0.5 ng/ml 
(95% vs 86%; p = 0.048). With different maintenance doses 
(degarelix 80 mg vs 120 mg vs 160 mg) testosterone level 
remained equal or below 0.5 ng/ml in 92%, 96% and 100% of 
patients until the end of the study. The median time to reach a 
PSA decline of 50% and 90% was 14 and 56 days. The only 
exception was the 200/80 group in whom the 90% PSA decline 
was reached after 84 days. After one year the median PSA 
reduction was 97%–98%.21
Phase III study
Recently, a randomized, open-label, three-arm phase III 
study to evaluate the efﬁ  cacy of degarelix versus leuprolide 
for achieving and maintaining testosterone suppression in 
patients with prostate cancer over a period of one year was 
published.14
Men aged 18 years or older with histological conﬁ  rmed 
adenocarcinoma of the prostate of all stages were included. 
Patients must have had a PSA of 2 ng/ml or more, a testoster-
one of 1.5 ng/ml or more, and an ECOG of 0–2. Previous or 
current androgen deprivation therapy was not allowed except 
some neoadjuvant or adjuvant androgen deprivation therapy of 
less than six months duration and discontinuation six months or 
longer ago. Patients considered for therapy with curative inten-
tion were excluded. Between February 2006 and October 2007, 
807 patients were screened. Of these, 620 patients were random-
ized and 610 patients received the study medication. Median age 
was 72 years (range 50–98 years), median PSA was 19 ng/ml 
(25th–75th percentile: 8.7–57 ng/ml), and median testosterone 
was 3.93 ng/ml (25th–75th percentile: 2.89–5.1 ng/ml).
Patients were randomized to one of the three following 
treatment arms: Arm A: degarelix 240 mg as initial dosage 
(2 × 3 ml sc) followed by 80 mg (1 × 4 ml sc) monthly; Arm B: 
degarelix 240 mg (2 × 3 ml sc) as initial dosage followed by 
160 mg (1 × 4 ml sc) monthly; Arm C: leuprolide 7.5 mg 
(1 × 1 ml intramuscularly [im]) monthly. A clinical ﬂ  are 
protection with bicalutamide (1 × 50 mg per os [po]) was 
allowed at the discretion of the investigator.
The primary endpoint of the study was the cumulative 
probability of testosterone suppression  0.5 ng/ml from 
28–364 days at monthly measurements. The trial also had 
14 secondary endpoints:
•  Proportion of patients with testosterone surge during the 
ﬁ  rst two weeks of treatment
•  Proportion of patients with testosterone levels of  0.5 ng/ml 
at day 3
• Probability  of  testosterone   0.5 ng/ml from 56–364 days
•  Probability of insufﬁ  cient testosterone response (deﬁ  ned 
as one or more testosterone levels   1 ng/ml or two 
or more testosterone measurements  0.5 ng/ml) from 
28–364 days
•  Frequency and size of testosterone increases at 255 days 
and/or 259 versus testosterone level at 252 days
•  Serum levels testosterone, LH, FSH, and PSA over time
•  Percentage change in PSA from baseline to 14–28 days
•  Time to PSA failure (PSA increase   50% from nadir 
and  5 ng/ml on two consecutive occasions at least two 
weeks apart)
•  Degarelix concentration over the ﬁ  rst month and through 
levels at 308 and 336 days
•  Frequency and severity of adverse events
• Clinically  signiﬁ  cant changes in laboratory values
•  Changes in electrocardiogram and vital signs
•  Quality of life on 0, 28, 84, 168, and 364 daysClinical Interventions in Aging 2009:4 219
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• Hot  ﬂ  ash frequency and hot ﬂ  ash score daily from study 
start until 354 days.
The primary endpoint (ie, testosterone levels   0.5 ng/ml 
from 28–364 days) was reached (in both ITT and per-protocol 
analyses) and thus it was demonstrated that degarelix 
(240/80 and 240/160) was noninferior to leuprolide (Table 1). 
The number of responders in the degarelix 240/80 and 
240/160 as well as the leuprolide 7.5 mg group were 202/207 
patients (97.2%), 199/202 patients (98.3%), and 194/201 
patients (96.4%).
One of the secondary endpoints was the proportion of 
patients with a testosterone level  0.5 ng/ml at day 3. As 
expected, 96.1% and 95.5% of patients treated with degare-
lix 240/80 and 240/160 had a testosterone level  0.5 ng/ml 
at day 3. In contrast, none of the patients in the leuprolide 
group achieved this result. In fact, the testosterone level in 
the latter group increased by 65% (median level 6.3 ng/ml, 
p   0.001). From days 28–364 the median testosterone levels 
were 0.082 ng/ml and 0.088 ng/ml in the degarelix groups 
and 0.078 ng/ml in the leuprolide group.
In the leuprolide group 23/201 (11%) patients received 
a concomitant medication with bicalutamide for clinical 
ﬂ  are protection deﬁ  ned as testosterone increase  15% from 
baseline on any two days during the ﬁ  rst two weeks. In this 
subgroup 17/23 (74%) had a testosterone surge and 144/178 
(81%) of the patients in the leuprolide group who did not 
receive bicalutamide had a testosterone surge and none of the 
patients treated with degarelix had a testosterone surge.
At days 14 and 28, PSA declined from baseline by 
64%/85% and 65%/83% in the 240/80 and 240/160 degarelix 
groups compared to 18%/68% in the leuprolide group. 
These differences in PSA reduction were statistically 
signiﬁ  cant (p   0.001). Insufﬁ  cient response to treatment was 
evident in 12 patients: four and two patients (1.9% and 1%) 
in the degarelix 240/80 and 240/160 groups as well as six 
patients (3%) in the leuprolide 7.5 mg group.14
Safety
The analysis of phase I, II, and III trials demonstrates that 
there is no evidence for allergic reaction associated with the 
treatment with degarelix which was the major disadvantage for 
clinical use of former GNRH antagonists like abarelix.14,20–22
Results from phase II trials
In the North American phase II trial including 127 patients 
with prostate cancer (of whom 87 patients completed the study) 
adverse events occurred in 87% of patients receiving degare-
lix 200/80 and 81% of patients receiving degarelix 200/60 
(Table 2).20 Most adverse events were mild to moderate but 
the exact number of mild, moderate, and severe adverse events 
was not given. However, 13% of patients had at least one severe 
adverse event. The most frequent adverse events were hot ﬂ  ashes 
Table 2 Published phase II and III trials on degarelix and prostate cancer: adverse events
Adverse event Gittelman20 (Phase II)
degarelix 200/80 vs 200/60
van Poppel21 (Phase II)
degarelix 200/80 vs 200/120 vs 200/160
vs 240/80 vs 240/120 vs 240/160
Klotz14 (Phase III)
240/80 vs 240/160 vs leuprolide 7.5
Any adverse event (%) 87/81 57/66/75/63/73/67 79/83/78
Hot ﬂ  ash (%) 38/48 47/25/31/37/27/33 26/26/21
Fatigue (%) 16/23 7/3/6/10/3/7 3/6/6
Injection site pain (%) 6/8 3/9/0/13/9/7 Not given
Injection site reaction (%) Not given Not given 35/44/1
Weight increase (%) 6/6 0/9/13/13/9/7 9/11/12
Back pain (%) 3/9 7/9/6/3/6/3 6/6/8
Nasopharyngitis (%) 11/11 Not given Not given
Dizziness (%) 11/9 Not given Not given
Arthralgia (%) 6/6 Not given 5/3/9
Constipation (%) 6/6 Not given 3/5/5
Hypertension (%) 6/6 Not given 6/7/4
Urinary tract infection (%) Not given 7/6/6/7/6/3 5/1/9
ALT increase (%) Not given 10/3/9/0/3/3 10/8/5
Cough (%) Not given 7/3/6/0/3/7 Not given
Diarrhea (%) Not given 3/9/6/0/3/7 Not given
Chills (%) Not given Not given 3/5/0
Abbreviation: ALT, alanine aminotransferase.Clinical Interventions in Aging 2009:4 220
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in 38% and 48% of patients followed by fatigue in 16% and 23% 
of patients. Nasopharyngitis (11% vs 11%) and dizziness (11% 
vs 9%) were other adverse events. Pain at the injection site was 
evident in 6% and 8% of patients treated with degarelix.20
In the European and South African phase II trial including 
187 patients with prostate cancer (of whom 147 patients 
completed the study) six different dose regimens of degarelix 
(200/80, 200/120, 200/160, 240/80, 240/120, and 240/160) 
were tested.21 Adverse events occurred in 57% to 75% 
of patients within these groups (Table 2). Most adverse 
events were mild to moderate but the exact number of mild, 
moderate, and severe adverse events was not given. How-
ever, 11% of patients had at least one severe adverse event. 
Hot ﬂ  ashes of mild to moderate intensity were documented 
in 33% (range 27%–47%) of cases. Fatigue occurred in 
6% (range 3%–10%) of patients and weight increase in 
9% (range 0%–13%) of patients. An increase of alanine 
aminotransferase was measured in 9% (range 3%–10%) 
of patients. Pain at the injection site was evident in 10% 
(range 0%–13%) of patients treated with degarelix.21
In the North American phase II trial, three patients (2%) 
died and another 11 patients (6%) died in the European and 
South African phase II trial. None of the reported deaths were 
considered to be related to degarelix.20,21
Results from a phase III trial
In the randomized phase III trial adverse event were reported in 
81% of 330% patients of the pooled degarelix groups and in 
78% of 156% patients of the leuprolide group (Table 2).14 The 
intensity of all reported adverse events in the pooled degarelix 
group versus the leuprolide group was mild in 283 (69%) 
versus 138 (69%) patients, moderate in 225 (55%) versus 
101 (50%) patients, and severe in 68 (17%) versus 26 (13%) 
patients. Serious adverse events were reported in 21 (10%) 
and 24 (12%) patients in the degarelix 240/80 and degarelix 
240/160 groups compared to 28 (14%) patients in the leupro-
lide group. The number of patients terminating the study due 
to adverse events was comparable in the three treatment arms: 
15 (7%) in the degarelix 240/80 group, 19 (9%) in the degarelix 
240/160 group, and 12 (6%) in the leuprolide group.
The most frequently reported adverse events in both groups 
were hot ﬂ  ashes (26% in the pooled degarelix group vs 21% 
in the leuprolide group). Patients treated with degarelix 
reported statistically signiﬁ  cant more injection site reactions 
than patients treated with leuprolide (40% in the pooled 
degarelix group vs  1% in the leuprolide group; p   0.001). 
These injection site reactions included pain, erythema, 
swelling, induration, and nodule. They were the reason for 
discontinuation in ﬁ  ve patients (1%) treated with degarelix 
although they occurred predominantly after the ﬁ  rst injection 
und were documented to be mild or moderate in intensity.
In 18 patients (4%) treated with degarelix, chills were an 
adverse event compared to no such event in the leuprolide 
group (p   0.01). Further signiﬁ  cant differences between the 
treatment groups were arthralgia (4% in the pooled degarelix 
group vs 9% in the leuprolide group; p   0.05) and urinary 
tract infections (3% in the pooled degarelix group vs 9% 
leuprolide group; p   0.01).
In each degarelix group, ﬁ  ve patients (2%) died compared 
to nine patients (4%) in the leuprolide group. None of the 
death was considered to be treatment-related.14
Conclusions
The administration of the GnRH antagonist degarelix is 
associated with a rapid, profound, and sustained suppression 
of testosterone in patients with prostate cancer. Results from 
the recently published randomized, open-label, three-arm 
phase III study showed that degarelix is not inferior to leup-
rolide at maintaining testosterone suppression over a one-year 
treatment period and degarelix was able to produce a faster 
testosterone suppression and PSA decline than leuprolide.14
In the last ten years, degarelix has run through various 
phase I and II trials and dose-ﬁ  nding was a major goal of 
these trials.22 As a result from these trials an initial dose of 
240 mg seems to be the best dose to achieve a clinically 
relevant testosterone suppression in more than 90% of patients 
within three days and in more than 95% of patients after one 
month.14,21 A maintenance dose of 80 mg and 160 mg degarelix 
every four weeks resulted in a profound and sustained testos-
terone suppression.14,21 In December 2008, degarelix at a dose 
of 240 mg sc followed by 80 mg sc every month has been 
approved for the treatment of advanced prostate cancer by the 
US Food and Drug Administration (FDA) and its approval by 
the European Medicines Agency (EMEA) has been recom-
mended.23 However, it is a clear disadvantage that degarelix 
is currently only available as a one-month formulation.
Degarelix has an immediate onset of action with no need 
for clinical ﬂ  are protection with an antiandrogen as required 
in some patients treated with GnRH agonists.24 This kind 
of action of degarelix might offer advantages especially in 
patients with advanced prostate cancer and a higher risk 
for symptoms associated with clinical ﬂ  are. Testosterone 
surge begins two to three days after administration of 
GnRH agonists.24 Theoretically, the median testosterone can 
increase by 100%. In the phase III trial it was demonstrated 
that median testosterone increased by 65%.14 This may be Clinical Interventions in Aging 2009:4 221
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associated with exacerbation of symptoms from prostate 
cancer. The symptoms may include bone pain, spinal cord 
compression, bladder outlet obstruction, cardiovascular 
problems, and so forth. However, there are wide discrepan-
cies in reports of the frequency and severity of acute clinical 
progression or clinical ﬂ  are that might result from the tes-
tosterone surge. The use of GnRH agonists for patients with 
metastatic prostate cancer can be associated with clinical ﬂ  are 
in approximately 10% of the patients.24 In contrast, patients 
with non-metastatic prostate cancer have very little risk for 
clinical ﬂ  are. Antiandrogen therapy reduces, but does not 
totally eliminate, clinical ﬂ  are in patients at high risk for this 
scenario.24 In the phase III trial it was voluntarily allowed to 
give bicalutamide for prevention of clinical ﬂ  are. However, 
only 11% patients received bicalutamide and no patient of the 
entire leuprolide group had documented clinical ﬂ  are.14
Abarelix (Plenaxis®; Praecis Pharmaceuticals, Cambridge, 
MA, USA) was the ﬁ  rst GnRH antagonist to be approved 
(in 2003) by the FDA for patients with advanced, symptomatic 
prostate cancer who cannot have or refuse other treatments for 
prostate cancer, such as other hormone treatments or surgery 
to remove the testicles.25 The reason for this restriction was 
that the administration of abarelix could be associated with 
acute systemic allergic reaction. In 15/1397 (1.1%) patients 
treated with abarelix this symptom was evident. In 14/15 
patients the symptoms occurred within eight minutes of 
injection. In 2005, Praecis Pharmaceuticals voluntarily dis-
continued promotional activities relating to abarelix in the US 
and the sale of abarelix for patients not currently on therapy.25 
However, in 2005 the drug was approved in Germany but not 
in other European countries. Since 2008, abarelix is avail-
able on the German market under the license of Speciality 
European Pharma.26 A systemic allergic reaction was not 
reported in any of the degarelix studies.14,20,21 Otherwise, in the 
randomized phase III trial 4% of the degarelix-treated patients 
reported chills versus none of the patients treated with leu-
prolide.14 These chills were neither discussed nor explained 
by the authors. Therefore, further reports on degarelix with 
long-term follow-up on efﬁ  cacy and safety – especially con-
cerning the allergic potential – are mandatory.
Also, it should be realized that 40% of patients experienced  
injection site reactions of degarelix compared to  1% at the 
im injection site of leuprolide.14 Why is the application of 
degarelix so painful? One explanation could be that the 
injected volume is rather high. In fact, 2 × 3 ml are injected 
to apply the initial dose of 240 mg degarelix.
If patients are diagnosed with prostate cancer the question 
today is: who needs androgen deprivation therapy? In a 
population-based cohort study of 19,271 patients older than 
65 years (median age 77 years) having prostate cancer and 
treated with androgen deprivation therapy (7,867 patients) or 
conservative management (11,047 patients) were studied.27 
Patients had a T1 disease in 49.8% (androgen deprivation 
group) compared to 64.2% (conservative management group) 
and the tumor was moderately and poorly differentiated in 
65% and 34.2% (androgen deprivation group) compared to 
83.7% and 14.2% (conservative management group). It was 
demonstrated that 10-year cancer-speciﬁ  c survival in patients 
receiving androgen deprivation therapy was 80.1% compared 
to 82.6% (Hazard ratio [HR]: 1.17, 95% conﬁ  dence interval 
[CI]: 1.03–1.33) in patients receiving conservative manage-
ment (deﬁ  ned as not receiving operative therapy, radiotherapy 
or androgen deprivation therapy within 180 during the ﬁ  rst 
days from diagnosis).27 Ten-year overall survival was 30.2% 
(androgen deprivation group) compared to 30.3% (conserva-
tive management group) and median overall survival was 
82 months in both groups. However, in patients with poorly 
differentiated prostate cancer it was shown that cancer spe-
ciﬁ  c survival was better in patients receiving androgen depri-
vation therapy (59.8% vs 54.3%, HR: 0.84, 95% CI: 0.7–1; 
p = 0.049). It is noteworthy that 75% of all patients received 
androgen deprivation therapy for a minimum of 18 months 
and 50% of patients for longer than 30 months.27
Not only the efﬁ  cacy of androgen deprivation therapy 
in terms of survival needs to be questioned but also pos-
sible adverse events. Androgen deprivation therapy itself 
is potentially associated with several adverse events. These 
include hot ﬂ  ashes, osteoporosis, loss of libido or impotence, 
psychological effects such as depression, memory difﬁ  culties 
or emotional lability, and others.28–32
Diabetes and cardiovascular disease are especially 
unwanted adverse events among older patients. However, 
there is growing evidence that androgen deprivation therapy 
is associated with an increased risk of cardiovascular disease 
and diabetes.28 In an observational study of a population-
based cohort of 73,196 patients older than 65 years (mean age 
74.2 years, standard deviation 5.8 years) having prostate can-
cer were investigated. The endpoints incident diabetes, coro-
nary heart disease, myocardial infarction, and sudden cardiac 
death occurred in 10.9%, 25.3%, 5.4%, and 4.5% of all cases. 
A total of 36.3% of patients received a GnRH agonist for a 
mean of 40% of time from diagnosis to censoring. This use 
of a GnRH agonist was associated with an increased risk of 
incident diabetes (adjusted HR: 1.44; P   0.001), coronary 
heart disease (adjusted HR: 1.16; p   0.001), myocardial 
infarction (adjusted HR: 1.11; p   0.03), and sudden cardiac Clinical Interventions in Aging 2009:4 222
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death (adjusted HR: 1.16; p   0.003). In 6.9% of patients 
an orchiectomy was performed for androgen deprivation 
therapy. It is noteworthy that in these patients a greater risk 
for diabetes (adjusted HR: 1.34; p   0.001) compared to no 
therapy was also found but this was not the case for coro-
nary heart disease (adjusted HR 0.99; p = 0.74), myocardial 
infarction (adjusted HR: 0.94; p = 0.44), and sudden cardiac 
death (adjusted HR: 1.91; p = 0.85).28
In summary, degarelix is associated with a rapid, profound, 
and sustained suppression of testosterone in patients with 
prostate cancer. Antiandrogens to prevent testosterone 
surge and prevent clinical ﬂ  are are not required. This may 
reduce costs and adverse events from the antiandrogen. 
Thus, a GnRH antagonist rather than a GnRH agonist may 
be used in patients with high tumor burden and/or acute 
problems such as spinal cord compression. In contrast to 
other GnRH antagonists degarelix was not associated with 
systemic allergy reaction. In the phase III trial, however, 
two adverse events occurred more often with degarelix 
compared to leurolide: injection site reactions (40% vs  1%) 
and unexplained chills following the application degarelix 
(4% vs 0%). Beside adverse events there is currently no three-
month formulation of degarelix available. A three-month 
interval for the application of GnRH agonists is convenient 
for the patient and currently the most often applied regimen. 
The phase III trial by Klotz and colleagues was not blinded 
and all patients “in whom androgen deprivation therapy was 
indicated” were included. What we don’t have for degarelix 
is data on cancer-speciﬁ  c survival and overall survival as 
well as any data in patients undergoing intermittent androgen 
deprivation therapy and complete androgen blockade. 
Finally, the average monthly cost of degarelix treatment 
is probably comparable to other hormone treatments for 
prostate cancer; in other words, degarelix is not cheaper. 
Therefore, the potential role of degarelix within a discussion 
about the indication for androgen deprivation therapy with 
regard to efﬁ  cacy, adverse events, and costs remains unclear 
and could be limited.
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